Reviewer’s report

Title: Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a novel glycopyrrolate metered-dose inhaler in study patients with chronic obstructive pulmonary disease

Version: 1 Date: 1 February 2014

Reviewer: Anthony D'Urzo

Reviewer’s report:

Excellent paper, very thorough, clear and novel. While the authors highlight very appropriately the selective nature of their population (bronchodilator responsiveness to antimuscaric challenge) it would be interesting to know how many patients of the total that were screened failed to met the reversibility criteria. Since this was a dose ranging study biased toward patients with reversibility, how might this influence dose selection (if any) for larger efficacy and safety trials?

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

Dr D'Urzo has received research, consulting and lecturing fees from GlaxoSmithKline, Sepracor, Schering Plough, Altana, Methapharma, AstraZeneca, ONO pharma, Merck Canada, Forest Laboratories, Novartis Canada/USA, Boehringer Ingelheim (Canada) Ltd, Pfizer Canada, SkyePharma, and KOS Pharmaceuticals and Almirall.